Latest 10-Q quarterly reports

Novavax, Inc. announced its second quarter 2026 financial results, reporting a substantial decrease in total revenue and a net loss, primarily driven by lower product sales and licensing income.

Centrus Energy Corp. reports on its HALEU expansion efforts, strategic partnerships, and financial performance for the quarter ended June 30, 2026, highlighting increased investments and evolving market dynamics.

Climb Bio's Q2 2026 report highlights progress in budoprutug and CLYM116 development, alongside a substantial cash position, but underscores continued operational losses and future financing needs.

Distribution Solutions Group, Inc. announced a definitive agreement to be acquired for $35.00 per share in cash, alongside reporting Q2 2026 results showing revenue growth driven by acquisitions and organic expansion.

ConocoPhillips announced robust financial results for the second quarter of 2026, driven by higher commodity prices and strategic asset acquisitions, while returning substantial capital to shareholders.

Vanda Pharmaceuticals Inc. filed its Q2 2026 Form 10-Q, detailing a net loss of $62.5 million, a decrease in HETLIOZ sales, and ongoing litigation, while also highlighting growth in Fanapt and progress in regulatory reviews for other products.

Collegium Pharmaceutical, Inc. reported a net loss for the quarter ended June 30, 2026, with revenues increasing due to the Azstarys acquisition, while operating expenses also rose significantly.

Cronos Group Inc. announced a substantial increase in net revenue for the second quarter of 2026, driven by strong performance in Israel and Canada, alongside a return to net income.

Viridian Therapeutics announced its Q2 2026 financial results, highlighting the FDA approval of veligrotug (Lumvoa) for thyroid eye disease and positive clinical trial data for elegrobart, while also reporting significant operating losses.

Vital Farms Inc. reported a net loss of $31.1 million for the 13-week period ended June 28, 2026, a significant downturn from a net income of $16.6 million in the prior year's comparable period, driven by increased costs and an unfavorable sales mix.

Graham Corporation reported a significant 29% increase in first-quarter net sales, driven by robust performance in the Defense sector and the strategic acquisition of FlackTek.

PepGen Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued research and development expenses, progress on its PGN-EDODM1 candidate, and a partial clinical hold in the U.S.

Sunrise Realty Trust, Inc. (SUNS) filed its Q2 2026 10-Q, detailing increased interest income and loan origination, alongside plans to acquire Southern Realty Trust Inc. (SRT).

Immunovant Inc. reported its second-quarter 2026 financial results, highlighting increased research and development expenses and a continued net loss, while emphasizing the strategic focus on its lead asset, IMVT-1402.

Roivant Sciences Ltd. filed its quarterly report for the period ended June 30, 2026, detailing a net loss of $290.6 million and increased operating expenses, while maintaining a substantial cash reserve of $3.8 billion.

Tarsus Pharmaceuticals announced significant year-over-year revenue growth in Q2 2026, driven by XDEMVY sales, and provided updates on its promising pipeline candidates.

Scholar Rock Holding Corporation's Q2 2026 Form 10-Q reveals continued net losses and operational expenses, with a focus on the resubmission of its apitegromab BLA to the FDA following a Complete Response Letter.

Unity Software Inc. announced its quarterly results, showcasing a significant increase in revenue driven by its Grow Solutions segment, while also detailing ongoing restructuring efforts and asset impairments.

Sionna Therapeutics details increased operating expenses and ongoing clinical trial progress in its Q2 2026 Form 10-Q filing.

Precision BioSciences reported its Q2 2026 financial results, highlighting progress in its gene editing programs PBGENE-HBV and PBGENE-DMD, while continuing to incur net losses.

REGENXBIO Inc. announced a significant increase in revenue driven by a $100 million milestone payment from AbbVie, alongside positive clinical trial updates for RGX-202 and RGX-121, and substantial capital raised.

Cullinan Therapeutics reports continued clinical development across its immunology and oncology pipelines, alongside significant operating losses and a cash runway extending through at least the next twelve months.

TIC Solutions, Inc. reported a net loss for the second quarter of 2026, despite significant revenue growth driven by the NV5 acquisition, while also addressing material weaknesses in internal controls.

Monte Rosa Therapeutics reported its second-quarter 2026 financial results, highlighting increased research and development expenses and a net loss, while maintaining substantial cash reserves and significant collaboration revenue from ongoing partnerships.

Commerce.com, Inc. filed its Q2 2026 Form 10-Q, detailing a slight increase in revenue driven by partner and services, alongside a significant reduction in operating expenses leading to improved profitability.

Vistance Networks reports Q2 2026 results marked by the strategic divestiture of its RUCKUS segment and a substantial special cash distribution to shareholders, while its core Aurora segment shows mixed performance.

Korro Bio, Inc. (KRRO) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing operating losses and strategic adjustments, including workforce reductions and the termination of a clinical trial.

Core Natural Resources, Inc. (CNR) announced a substantial increase in net income for the second quarter of 2026, driven by strong performance in its metallurgical and high CV thermal segments, alongside significant insurance recoveries.

Cartesian Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its autoimmune disease cell therapy development, securing new debt financing, and continued operational losses.

Tripadvisor reports a revenue decrease in its Hotels and Other segment and a slight increase in Experiences bookings, while advancing the sale of TheFork.